All In Biotech

BLA 761210 · Janssen Biotech

Rybrevant

Amivantamab-Vmjw · Injection

NovelBreakthrough therapyAccelerated approvalPriority review

CDER novel approval, May 21, 2021: To treat a subset of non-small cell lung cancer

Last checked: Nov 20, 2026Latest source record: Nov 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

May 21, 2021

Approved uses

6

Original approval plus efficacy supplements

Registered trials

52

8 Phase 3, 19 recruiting

FAERS reports

3,576

2,464 serious, 273 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2025.

RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT, in combination with carboplatin and pemetrexed, is indicated...

Mechanism: Amivantamab-vmjw is a bispecific antibody that binds to the extracellular domains of EGFR and MET. In in vitro and in vivo studies amivantamab-vmjw was able to disrupt EGFR and MET signaling functions in mutation models of exon 19 deletions, exon 21 L858R substitutions, and exon 20 insertions through blocking ligand binding or degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 14, 2025 Supplement 9 · Efficacy LabelLetter
  • Sep 19, 2024 Supplement 4 · Efficacy LetterLabel
  • Aug 19, 2024 Supplement 5 · Efficacy · priority review LetterLabel
  • Mar 1, 2024 Supplement 3 · Efficacy · priority review LabelLetter
  • Nov 4, 2022 Supplement 2 · Efficacy LabelLetter
  • May 21, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
1 products under this application
  • RYBREVANT · AMIVANTAMAB-VMJW 350MG/7ML(50MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amivantamab" as an intervention, any sponsor and status, largest first.

All 52 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infusion related reaction756
  • rash507
  • off label use267
  • paronychia178
  • dyspnoea128
  • non-small cell lung cancer118
  • nausea117
  • skin toxicity89
  • oxygen saturation decreased88
  • stomatitis87
  • fatigue84
  • hypotension84

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202166
2022154
2023203
2024592
20251,482
20261,079

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rybrevant (Amivantamab-Vmjw)

2024 spending

$3.0M

Beneficiaries

28

131 claims

Per beneficiary

$108,818

$509.69 per unit

View as table
YearSpending
2020$0
2021$287,543
2022$521,420
2023$1,309,712
2024$3,046,904

Part B: Rybrevant (Amivantamab-Vmjw) · HCPCS J9061

2024 spending

$70.1M

Beneficiaries

839

6,014 claims

Per beneficiary

$83,500

2024 ASP limit $20.30 per unit

View as table
YearSpending
2020$0
2021$0
2022$20,437,822
2023$23,714,518
2024$70,056,728

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 53 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.